One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes

One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Diabetes & Metabolism - Volume 43, Issue 3, June 2017, Pages 275-279

C. Vatier, L. Arnaud, X. Prieur, B. Guyomarch, C. Le May, E. Bigot, M. Pichelin, A. Daguenel, M.-C. Vantyghem, J.-F. Gautier, C. Vigouroux, B. Cariou,